Koichi Azuma 研究室

主宰者：Koichi Azuma

九州大学・Kyushu University Hospital

AI 要約（直近 5 年の研究成果）

Koichi Azuma研究室は、肺がんと肝炎ウイルス感染症の治療法開発を中心に研究を展開しています。特に非小細胞肺がんに対する分子標的薬と免疫療法の組み合わせ治療に力を注いでおり、EGFR遺伝子変異やKRAS遺伝子変異といった特定の遺伝子異常を持つがんの患者に対して、既存の治療法よりも有効な治療レジメンを開発・評価しています。また、免疫療法に対する治療反応を予測するための生物学的マーカー（バイオマーカー）の探索も積極的に行い、血液中の免疫関連物質や腸内細菌叢などが治療効果とどのように関連するかを調べています。一方、C型肝炎ウイルスの治療に関しては、直接作用型抗ウイルス薬による治療後の患者の長期的な予後や、肝がん発症リスクの層別化に関する大規模な多施設研究を行っています。さらに、B型肝炎患者の腎機能悪化を防ぐための治療戦略の検討や、化学療法と放射線治療を組み合わせた後の免疫療法に関連する合併症のメカニズム解明も進めています。これらの研究は主に臨床データの解析と患者血液サンプルの分析を通じて、より多くの患者に恩恵をもたらす治療法の確立を目指しています。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（100 件）

[2026] Long‐Term Mortality Following Hepatitis C Cure in a Real‐World Multinational Cohort
DOI: https://doi.org/10.1111/liv.70561
[2025] Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1078-0432.ccr-24-3532
[2025] Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC
DOI: https://doi.org/10.1038/s41467-025-58186-7
[2025] Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset
DOI: https://doi.org/10.1016/j.lungcan.2025.108496
[2025] 38P: Two years of follow-up data of a phase II clinical trial of atezolizumab with bevacizumab for patients with PD-L1 high expression non-squamous non-small cell lung cancer (WJOG10718L/@ Be Study)
DOI: https://doi.org/10.1016/s1556-0864(25)00233-3
[2025] Long‐Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct‐Acting Antivirals
DOI: https://doi.org/10.1111/jgh.16892
[2025] The Impacts of Active and Inactive Ghrelin on Cachexia and Immune Checkpoint Inhibitor Monotherapy in Patients with Non-Small Cell Lung Cancer
DOI: https://doi.org/10.1159/000543425
[2025] A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET)
DOI: https://doi.org/10.1016/j.jtho.2025.01.006
[2025] A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040)
DOI: https://doi.org/10.1016/j.jtho.2024.12.027
[2025] Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study)
DOI: https://doi.org/10.1016/j.ctarc.2025.101008

続きを表示（残り 90 件）

[2025] A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study
DOI: https://doi.org/10.1016/j.ejca.2025.115693
[2025] Biomarker study on pneumonitis in durvalumab maintenance therapy after chemoradiotherapy for stage III non-small cell lung cancer
DOI: https://doi.org/10.1186/s12885-025-15467-0
[2025] P3.12.33 The Primary Endpoint Analysis of RELAY-Effusion; a Phase II Study of Ramucirumab Plus Erlotinib in EGFR-Mutated NSCLC With Pleural Effusion
DOI: https://doi.org/10.1016/j.jtho.2025.09.895
[2025] Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab
DOI: https://doi.org/10.21037/tlcr-2025-563
[2025] Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study
DOI: https://doi.org/10.1016/j.lungcan.2025.108772
[2025] Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited‐Stage Small‐Cell Lung Cancer in the Phase 3 <scp>ADRIATIC</scp> Trial
DOI: https://doi.org/10.1111/cas.70188
[2025] Five‐Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment
DOI: https://doi.org/10.1111/jgh.70059
[2025] Evaluation of Potential Stability of Stainless Steel for Application to Quasi-Reference Electrode
DOI: https://doi.org/10.1149/ma2025-01623060mtgabs
[2025] Exploration of plasma factor profiles involved in tumor growth factors in non-small cell carcinoma patients with interstitial pneumonia
DOI: https://doi.org/10.1016/j.resinv.2025.06.012
[2025] Hemophagocytic Lymphohistiocytosis Due to Ipilimumab plus Nivolumab in a Patient with Pleural Mesothelioma
DOI: https://doi.org/10.2482/haigan.65.179
[2025] SMARCA4-deficient Undifferentiated Thoracic Tumor That Responded to Pembrolizumab Monotherapy in a Patient with a Poor Performance Status
DOI: https://doi.org/10.2482/haigan.65.175
[2025] Final results of afatinib plus chemotherapy with genomic profiling in osimertinib-refractory EGFR-mutant NSCLC: NEJ025B.
DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.8596
[2025] WED-290 Effectiveness and renal safety following switching to tenofovir alafenamide in patients with chronic hepatitis B: Results from a five-year, multicenter cohort study
DOI: https://doi.org/10.1016/s0168-8278(25)02099-9
[2025] Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer
DOI: https://doi.org/10.1016/j.lungcan.2025.108578
[2024] Different Effects of Hypoxia-Inducible FactorProlyl Hydroxylase Inhibitors on Serum Lipid Levels in Patients on Hemodialysis
DOI: https://doi.org/10.29011/2575-7903.001362
[2024] Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy
DOI: https://doi.org/10.1007/s00262-024-03781-8
[2024] Thoracic Angiosarcoma Arising from Chronic Tuberculous Pyothorax
DOI: https://doi.org/10.2169/internalmedicine.4088-24
[2024] 132P The potential of VEGF-A in the peripheral blood serum as a biomarker of response in the addition of bevacizumab with chemotherapy-combined immunotherapy for metastatic nonsquamous non-small cell lung cancer
DOI: https://doi.org/10.1016/j.annonc.2024.08.140
[2024] Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial
DOI: https://doi.org/10.1016/s2213-2600(24)00185-1
[2024] Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study
DOI: https://doi.org/10.1016/j.cllc.2024.07.001
[2024] Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors
DOI: https://doi.org/10.3389/fcell.2023.1324898
[2024] Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study
DOI: https://doi.org/10.14218/jcth.2024.00089
[2024] A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation–positive non-small cell lung cancer (OPEN/TORG2040).
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8552
[2024] Sa1616 MORTALITY RATES AMONG PATIENTS SUCCESSFULLY TREATED FOR HEPATITIS C: A REAL WORLD MULTINATIONAL COHORT STUDY
DOI: https://doi.org/10.1016/s0016-5085(24)04132-5
[2024] Evaluation of Corrosion Potential Stability of Stainless Steels in Dilute Electrolyte Solution for Application to a Quasi-Reference Electrode Used in Electrochemical Sensing System
DOI: https://doi.org/10.3390/chemosensors13010004
[2024] Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
DOI: https://doi.org/10.1016/j.jtocrr.2024.100784
[2024] 1O Exploration of gut microbiota biomarkers in treatment-naïve advanced NSCLC patients undergoing chemo-immunotherapy: Insights from the phase III trial, JCOG2007 (NIPPON)
DOI: https://doi.org/10.1016/j.iotech.2024.100885
[2024] Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia
DOI: https://doi.org/10.1016/j.lungcan.2024.107992
[2024] Final analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer KRAS G12C mutation.
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8616
[2024] Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8504
[2024] Efficacy of immunotherapy in first-line treatment for non-small cell lung cancer with HER2 mutation: Results from LC-SCRUM-Asia.
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8629
[2024] Phase 2 study of pembrolizumab plus pemetrexed for older patients with non-squamous non-small cell lung cancer with PD-L1 tumor proportion score of less than 50%: CJLSG1901.
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8540
[2024] OS-062 Long-term liver morbidity and mortality after HCVelimination by direct-acting antivirals in patients with chronic hepatitis C: results from a large-scale, multicenter cohort study
DOI: https://doi.org/10.1016/s0168-8278(24)00503-8
[2024] First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study
DOI: https://doi.org/10.1093/jjco/hyad195
[2024] Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort
DOI: https://doi.org/10.1158/2767-9764.crc-23-0313
[2023] The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).
DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.9006
[2023] Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1001/jamaoncol.2023.5258
[2023] Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
DOI: https://doi.org/10.1016/j.jtocrr.2023.100613
[2023] O7-2 A phase II study to assess the efficacy of osimertinib in patients with EGFR MT(+)T790M(-) NSCLC
DOI: https://doi.org/10.1016/j.annonc.2023.09.128
[2023] MO55-4 Prognostic impact and predictive biomarkers of immune checkpoint inhibitor-induced interstitial lung disease for non-small cell lung cancer
DOI: https://doi.org/10.1016/j.annonc.2023.09.290
[2023] MA05.10 Patient-Initiated a Phase II study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutated T790M-Negative NSCLC
DOI: https://doi.org/10.1016/j.jtho.2023.09.149
[2023] P2.05-07 Roles of p53 and AXL Expressions on the Efficacy of ICI-Based Therapy in Patients with EGFR Mutated Lung Cancer after Osimertinib
DOI: https://doi.org/10.1016/j.jtho.2023.09.534
[2023] EP11.01-11 Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors
DOI: https://doi.org/10.1016/j.jtho.2023.09.1161
[2023] Abstract C009: Biomarker analyses for predicting the benefit from immune checkpoint inhibitors in EGFR-mutated non-small cell lung cancer
DOI: https://doi.org/10.1158/1535-7163.targ-23-c009
[2023] MO1-1 LIGHT-NING 2nd interim analysis: Early safety of 1L nivolumab + ipilimumab +/- chemotherapy for NSCLC in Japan
DOI: https://doi.org/10.1016/j.annonc.2023.09.147
[2023] Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors
DOI: https://doi.org/10.1002/cam4.6549
[2023] Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1001/jamaoncol.2023.3309
[2023] Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer
DOI: https://doi.org/10.1016/j.lungcan.2023.107351
[2023] Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures
DOI: https://doi.org/10.1136/jitc-2023-006788
[2023] A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study.
DOI: https://doi.org/10.1200/jco.2023.41.17_suppl.lba9009
[2023] Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial
DOI: https://doi.org/10.1016/j.cllc.2023.05.008
[2023] Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer
DOI: https://doi.org/10.1007/s00262-023-03370-1
[2023] A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation positive non-squamous, advanced non–small-cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B.
DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.9044
[2023] Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab.
DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.8593
[2023] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
DOI: https://doi.org/10.1007/s00262-023-03464-w
[2023] Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
DOI: https://doi.org/10.1016/j.jtho.2023.04.021
[2023] EP101 VIROLOGICAL AND BIOCHEMICAL EFFECTIVENESS OF SEQUENTIAL NUCLEOS(T)IDE ANALOGUE TREATMENT WITH TENOFOVIR ALAFENAMIDE FOR PATIENTS WITH CHRONIC HEPATITIS B: 144-WEEK RESULTS FROM A REAL-WORLD, MULTICENTER STUDY
DOI: https://doi.org/10.1016/s0016-5085(23)04331-7
[2023] Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors
DOI: https://doi.org/10.1111/1759-7714.14881
[2023] Enhanced immune complex formation in the lungs of patients with dermatomyositis
DOI: https://doi.org/10.1186/s12931-023-02362-0
[2023] Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study
DOI: https://doi.org/10.1016/j.ejca.2023.02.023
[2023] Proton Beam Therapy as a Curative Treatment for a Young Case of Unresectable Tracheal Adenoid Cystic Carcinoma
DOI: https://doi.org/10.2169/internalmedicine.0574-22
[2023] A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy
DOI: https://doi.org/10.1016/j.lungcan.2023.01.011
[2023] SARS-CoV-2 Antibodies in Patients on Hemodialysis after the BNT162b2 mRNA Vaccination
DOI: https://doi.org/10.29011/2575-7903.001303
[2023] Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
DOI: https://doi.org/10.1186/s12885-022-10467-w
[2023] Phase 2 Study of Osimertinib in Combination with Platinum and Pemetrexed in Patients with Previously Untreated EGFR–Mutated Advanced Non–Squamous Non–Small Cell Lung Cancer: The OPAL Study
DOI: https://doi.org/10.2139/ssrn.4329566
[2022] A Phase II Study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutation-Positive NSCLC in Whom Systemic Disease (T790M-Negative) Progressed after Treatment with First- Or Second-Generation EGFR TKIS and Platinum-Based Chemotherapy
DOI: https://doi.org/10.2139/ssrn.4309667
[2022] Surface morphology live-cell imaging reveals how macropinocytosis inhibitors affect membrane dynamics
DOI: https://doi.org/10.1016/j.electacta.2022.141783
[2022] Phase <scp>II</scp> study of durvalumab (<scp>MEDI</scp> 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (<scp>LOGIK</scp> 2003)
DOI: https://doi.org/10.1111/1759-7714.14727
[2022] A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
DOI: https://doi.org/10.1016/j.jtocrr.2022.100388
[2022] Clinical significance of interstitial lung abnormalities and immune checkpoint <scp>inhibitor‐induced</scp> interstitial lung disease in patients with <scp>non‐small</scp> cell lung cancer
DOI: https://doi.org/10.1111/1759-7714.14718
[2022] A case of cytokine release syndrome accompanied with <scp>COVID</scp>‐19 infection during treatment with immune checkpoint inhibitors for non‐small cell lung cancer
DOI: https://doi.org/10.1111/1759-7714.14632
[2022] Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer
DOI: https://doi.org/10.1016/j.esmoop.2022.100527
[2022] P29-1 LIGHT-NING: An observational study of nivolumab plus ipilimumab with or without chemotherapy for 1st line NSCLC in Japan
DOI: https://doi.org/10.1016/j.annonc.2022.05.276
[2022] PS1-2 CLIP1-LTK: a novel target in non-small cell lung cancer
DOI: https://doi.org/10.1016/j.annonc.2022.05.062
[2022] Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study
DOI: https://doi.org/10.1111/apt.17107
[2022] Abstract 5153: Longitudinal cell-free DNA analysis in phase I study evaluating afatinib in combination with osimertinib in patients who failed prior osimertinib treatment
DOI: https://doi.org/10.1158/1538-7445.am2022-5153
[2022] A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.9097
[2022] AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer
DOI: https://doi.org/10.1038/s41598-022-12995-8
[2022] Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
DOI: https://doi.org/10.1016/j.jtho.2022.05.006
[2022] Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model
DOI: https://doi.org/10.1136/jitc-2021-004420
[2022] Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)
DOI: https://doi.org/10.1016/j.lungcan.2022.04.004
[2022] Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
DOI: https://doi.org/10.1136/jitc-2021-004025
[2022] Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study
DOI: https://doi.org/10.1007/s12072-021-10295-3
[2022] Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
[2021] MA02.05 A Phase I Study of Afatinib in Combination With Osimertinib in Patients After Failure of Prior Osimertinib
DOI: https://doi.org/10.1016/j.jtho.2021.08.114
[2021] A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
DOI: https://doi.org/10.1158/1078-0432.ccr-21-3194
[2021] Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)
DOI: https://doi.org/10.2147/cmar.s336262
[2021] Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non–Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L)
DOI: https://doi.org/10.1016/j.cllc.2021.10.007
[2021] Long‐term hepatic function of patients with compensated cirrhosis following successful direct‐acting antiviral treatment for hepatitis C virus infection
DOI: https://doi.org/10.1111/jgh.15703
[2021] LBA44 Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study
DOI: https://doi.org/10.1016/j.annonc.2021.08.2123

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（100 件）

科研費（0 件）

所属学会・役職（0 件）